| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1ccacd6cad7e35486edea254c8e41ac2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16621
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
| filingDate |
2017-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ef6849322cffc2c0f40467281edac3c |
| publicationDate |
2017-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017319639-A1 |
| titleOfInvention |
Oncolytic viruses & methods of use thereof |
| abstract |
Modified and improved oncolytic viruses (and methods of use thereof) are disclosed. More particularly, modified and oncolytic human herpesviruses (and methods of use thereof) are disclosed, which include a modified amino acid sequence that includes a deletion in a region that represents the amino terminus of glycoprotein K. The modified and oncolytic human herpesviruses include a deletion of amino acid residues 31-68, relative to the wild type amino acid sequence of glycoprotein K in human herpesviruses. Isolated vector constructs that encode such oncolytic viruses are also disclosed. In addition, methods for using such oncolytic viruses to treat cancers are disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021158969-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020028719-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3829608-A4 |
| priorityDate |
2016-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |